The wait for a reversible male contraceptive may finally be coming to an end. The World Health Organization has announced that such options could reach the market within five to ten years, marking a potential milestone in reproductive health equity after more than a century of limited choices for men.
For nearly 140 years, the landscape of male contraception has remained largely unchanged since the first vasectomy was performed in the 1890s. While women have seen waves of innovation—from the contraceptive pill introduced in 1961 to modern implants and IUDs—men have had little beyond condoms and withdrawal. This imbalance has placed the burden of contraception predominantly on women, despite growing calls for shared responsibility.
The Science Behind Male Hormonal Contraception
Unlike female hormonal methods that regulate ovulation, male contraceptives focus on suppressing sperm production. Testosterone-based treatments work by tricking the brain into halting sperm creation while maintaining healthy hormone levels. Early trials conducted by the WHO in the late 1980s showed promising results, with over 60% of participants achieving zero sperm count and successfully using the method as their sole form of contraception for a year.
Subsequent research refined the approach by combining testosterone with progestin, a synthetic hormone commonly used in hormone replacement therapy. This combination significantly improved effectiveness while reducing the amount of testosterone needed, potentially enhancing long-term safety. Recent studies, including a major international trial funded by the US National Institutes of Health, have tested daily testosterone/progestogen gels with encouraging outcomes.
Barriers That Slowed Progress
Despite proven efficacy, the development of male contraceptives has faced significant obstacles. Corporate interests have played a major role, with pharmaceutical companies reluctant to invest in what they perceive as a challenging market. Bayer, for instance, discontinued funding for male contraceptive research in the early 2000s despite successful trials, citing concerns about male compliance and convenience.
Medical professionals have also expressed caution about altering male hormone levels, reflecting broader cultural hesitations about tampering with men’s bodies—a scrutiny not equally applied to women’s reproductive health. Additionally, the lucrative female contraceptive market, projected to reach nearly $30 billion by 2034, has provided little incentive for pharmaceutical giants to disrupt the status quo.
Shifting Attitudes and Growing Demand
Public opinion appears ready for change. A recent WHO study found that 72% of men and 76% of women across diverse countries expressed willingness to use new male contraceptives. More than 85% of women surveyed indicated they would trust their partners to take responsibility for contraception. This shift is particularly pronounced in the United States, where interest in male contraceptives rose from 39% to 49% following the overturning of Roe v. Wade.
Documentary filmmaker Billie J. Porter, who explored the slow evolution of male hormonal contraception in her film “It’s Different For Girls,” argues that the delay stems from “corporate greed and systemic misogyny.” Her research revealed a pattern of excluding women’s voices from early safety discussions and prioritizing male comfort over reproductive equity.
The Path Forward
As clinical trials continue globally, researchers remain optimistic. Professor Richard Anderson of Edinburgh University, who has led multiple studies, notes that participant dropout rates due to side effects have been remarkably low—often just a few percent. In Edinburgh’s cohort specifically, participants tolerated the treatment exceptionally well, with many female partners expressing relief at taking a break from birth control.
Crucially, fertility suppression has proven fully reversible. Across all trial follow-ups, typically after up to 18 months of use, sperm counts returned to normal, and many couples conceived healthy children afterward. The main challenge now lies in securing adequate funding for larger-scale production and distribution.
Why it Matters
The imminent arrival of reversible male contraceptives represents more than a medical advancement—it signals a potential rebalancing of reproductive responsibility. For decades, the physical and emotional burden of contraception has fallen disproportionately on women, creating health risks and relationship tensions. As restrictions on abortion access expand globally, particularly in the United States following the overturning of Roe v. Wade, the demand for reliable contraception has never been greater. Beyond individual benefits, shared contraceptive responsibility could reshape intimate relationships, reduce unintended pregnancies, and decrease reliance on abortion services. However, success will depend not only on scientific proof but also on overcoming cultural resistance, ensuring affordable access, and addressing concerns about side effects that have historically been accepted as routine for women but scrutinized more heavily for men. The stakes extend far beyond personal choice—they touch on fundamental questions of gender equality and bodily autonomy in the 21st century.
